Long-Term Outcomes of Pulmonary Vein Isolation in Patients With Brugada Syndrome and Paroxysmal Atrial Fibrillation

Antonio Bisignani, Giulio Conte, Luigi Pannone, Juan Sieira, Alvise Del Monte, Felicia Lipartiti, Gezim Bala, Vincenzo Miraglia, Cinzia Monaco, Erwin Ströker, Ingrid Overeinder, Alexandre Almorad, Anaïs Gauthey, Livia Franchetti Pardo, Matthias Raes, Olivier Detriche, Pedro Brugada, Angelo Auricchio, Gian-Battista Chierchia, Carlo de Asmundis

Onderzoeksoutput: Articlepeer review


Background Pharmacological treatment of atrial fibrillation (AF) in the setting of Brugada syndrome (BrS) is challenging. In addition, patients with BrS with an implantable cardioverter-defibrillator (ICD) might experience inappropriate shocks for fast AF. Long-term outcome of pulmonary vein isolation in BrS has not been well established yet, and it is still unclear whether pulmonary vein triggers are the only pathophysiological mechanism of AF in BrS. The aim of the study is to assess the long-term outcomes in patients with BrS undergoing pulmonary vein isolation for paroxysmal AF compared with a matched cohort of patients without BrS. Methods and Results Sixty patients with BrS undergoing pulmonary vein isolation with cryoballoon catheter ablation for paroxysmal AF were matched with 60 patients without BrS, who underwent the same procedure. After a mean follow-up of 58.2±31.7 months, freedom from atrial tachyarrhythmias was achieved in 61.7% in the BrS group and in 78.3% in the non-BrS group (log-rank P=0.047). In particular, freedom from AF was 76.7% in the first group and in 83.3% in the second (P=0.27), while freedom from atrial tachycardia/atrial flutter was 85% and 95% (P=0.057). In the BrS group, 29 patients (48.3%) had an ICD and 8 (27.6%) had a previous ICD-inappropriate shock for fast AF. In the BrS cohort, ICD-inappropriate interventions for AF were significantly reduced after ablation (3.4% versus 27.6%; P=0.01). Conclusions Pulmonary vein isolation in patients with BrS was associated with higher rate of arrhythmic recurrence. Despite this, catheter ablation significantly reduced inappropriate ICD interventions in BrS patients and can be considered a therapeutic strategy to prevent inappropriate device therapies.

Originele taal-2English
TijdschriftJournal of the American Heart Association
Nummer van het tijdschrift15
Vroegere onlinedatum20 jul 2022
StatusPublished - 2 aug 2022

Bibliografische nota

Funding Information:
Dr de Asmundis reports speaker fees for Medtronic, Biotronik, Biosense Webster, Abbott, and Boston Scientific; teaching honoraria from Medtronic, Biotronik, Abbott, and Boston Scientific; and proctoring honoraria from Medtronic, Abbott, and Biotronik. Dr Chierchia reports speaker fees for Medtronic, Biotronik, Biosense Webster, and Abbott; teaching honoraria from Medtronic and Biotronik; and proctoring honoraria from Medtronic. Dr Bisignani is consultant for Biotronik. Dr Conte has received a research grant (PZ00P3_180055) from the Swiss National Science Foundation. Dr Auricchio is a consultant with Boston Scientific, Backbeat, Biosense Webster, Cairdac, Corvia, Medtronic, Merit, Microport CRM, and Philips; participates in clinical trials sponsored by Boston Scientific, Medtronic, Microport CRM, and Philips; and has intellectual properties assigned to Boston Scientific, Biosense Webster, and Microport CRM. Dr Brugada reports consulting fees and speaker honoraria from Medtronic. The remaining authors have nothing to disclose.

Publisher Copyright:
© 2022 The Authors.

Copyright 2022 Elsevier B.V., All rights reserved.


Duik in de onderzoeksthema's van 'Long-Term Outcomes of Pulmonary Vein Isolation in Patients With Brugada Syndrome and Paroxysmal Atrial Fibrillation'. Samen vormen ze een unieke vingerafdruk.

Citeer dit